Lv555
1450 积分 2025-03-01 加入
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study
5天前
已完结
The carbon tetrachloride model in mice
2个月前
已完结
Gout
2个月前
已完结
Engineered extracellular vesicles with surface FGF21 and enclosed miR-223 for treating metabolic dysfunction-associated steatohepatitis
3个月前
已完结
Fibroblast growth factor 21
3个月前
已完结
FGF21 promotes migration and differentiation of epidermal cells during wound healing via SIRT1-dependent autophagy
3个月前
已完结
Double knockout of FFAR4 and FGF21 aggravates metabolic disorders in mice
4个月前
已完结
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
4个月前
已完结
Effective and safe delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles in vitro and in vivo
4个月前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study
5个月前
已完结
皖公网安备34019202002308
